


What are the risk-factors with an impact on fatality rate in fulminant hepatitis A?

***Daniel Shouval***  
***Liver Unit***  
***Hadassah-Hebrew University***  
***Jerusalem, Israel***

# Hepatitis in Chimpanzees inoculated with HAV



\*Adopted from Nainan et al. *Clinical Microbiology Reviews* 2006;19;:63

# Cumulative Experience

- Acute HAV infection resolves spontaneously in > 99% of infected individuals
- Fulminant hepatitis is rare with a wide range of estimated rates, up to 1:10,000 or more in immuno-competent individuals
- Patients with chronic liver disease are at an increased risk for developing severe or fulminant hepatitis
- Mortality in fulminant hepatitis is rare and linked to hepatitis A in older age > 50 y

# Patients Survival in Fulminant Viral Hepatitis Without OLT\*

## Etiology

## Survival

|                    |            |
|--------------------|------------|
| <b>Hepatitis A</b> | <b>66%</b> |
| <b>Paracetamol</b> | <b>50%</b> |
| <b>Hepatitis B</b> | <b>39%</b> |
| <b>Hepatitis C</b> | <b>20%</b> |
| <b>Halothane</b>   | <b>13%</b> |

---

*\*O'Grady et al, Gastroenterology 1988; 94: 1186.*

# Age-specific Mortality Due to Hepatitis A

| <u>Age group<br/>(years)</u> | <u>Case-Fatality<br/>(per 1000)</u> |
|------------------------------|-------------------------------------|
| <5                           | 3.0                                 |
| 5-14                         | 1.6                                 |
| 15-29                        | 1.6                                 |
| 30-49                        | 3.8                                 |
| >49                          | 17.5                                |
| <b>Total</b>                 | <b>4.1</b>                          |

Source: US Viral Hepatitis Surveillance Program, 1983-1989  
Similar data CDC Hepatitis surveillance report No 58,2003 p 1

# Fulminant Hepatitis A in children

Number of reports is rising?

- Turkey 4 cases (6/04-11/06)
- UK 9 cases (1991-2000)
- Argentina 128 cases (5/82-9/02)
- Argentina 41 cases (9/03-1/06)
- Brazil 13 cases (1998-2007)

***Reports are retrospective and released by individual centers***

*J Viral Hepatitis 2008;15:S66; J Ped Gastroenterol & Nutr 2005;40:575; Pediat Crit Care Med 2002;3:227; Liver Int 2007; Arch Dis Child 2008;93:48*



# Rising Incidence of Fulminant Hepatitis A irrespective of age\*

| Year | %    |
|------|------|
| 2003 | 0    |
| 2004 | 3.4  |
| 2005 | 3.2  |
| 2006 | 6.0  |
| 2007 | 7.7  |
| 2008 | 13.0 |

- 35/568 HAV patients had fulminant hepatitis (KCH)
- Spontaneous survival 20/35 (57.1%)
- Transplanted 13/35 (37.1%)
- Died 5/35 (14.3%)



**Total survival 85.7%**

## Etiology of Acute Liver Failure in Adults



Hepatitis


## Etiology of Acute Liver Failure in 3-18y olds



Hepatitis




# Trends in the incidence of hepatitis A virus related acute liver failure in the United States.



The incidence of patients undergoing liver transplantation for HAV related ALF in the UNOS database significantly declined between 1988 and 2005 ( $P < .001$ ). Similarly, the frequency of HAV patients enrolled in the ALFSG significantly declined between 1998 and 2005 ( $P = .007$ ).


*\*Taylor RM et al. Hepatology 2006;44:1589*

**Outcomes of patients with HAV listed for liver transplantation in the UNOS database. All patients were listed between 1/98 and 9/15/05**



*\*Taylor RM et al. Hepatology 2006;44:1589*

**Outcomes of patients with HAV enrolled in the Acute Liver Failure Study Group\***  
**All patients were enrolled between 1/98 and 9/15/05**  
**and followed for 3 weeks after enrollment**



# **Outcomes of patients with HAV enrolled in the Acute Liver Failure Study Group\***

**All patients were enrolled between 1/98 and 9/15/05  
and followed for 3 weeks after enrollment**

## **Results**

- 16 HAV patients recovered spontaneously (55%)**
- 13 HAV patients were transplanted or died (45%)**

# Factors with an impact on fatality rate in fulminant hepatitis A

- **Host**

- **Age**

- **co-infection with hepatotropic viruses**

- **immune response?**

- **Virus**

- **genomic variations**

- **virulence**

- **Treatment for liver failure**

- **improved intensive care**

- **liver transplantation**

# Risk factors associated with fulminant hepatitis A and liver failure

- Age of infection
  - Chronic liver disease and co-infection with other hepatotropic viruses (HBV, HCV)
  - Intake of paracetamol
  - Viral factors ?
- 
- Pregnancy ???

# Increased severity of HAV infection

- In the elderly: hospitalization rates rose from 3% in 40-49y olds to 42% <age of 70y (*Brown&Persley Southern Med J 2002;95:826*)
- In HCV, HBV and HIV co-infection (*Laurence JC Am J Med 2005;118:75*)
- In pregnancy (*Elinav E et al. \* Gastroenterology 2006;130:1129, Gall A Am J Med 2005;118:96S*)

---

\*34/79458 acute hepatitis

13/34 Acute HAV 'with premature contractions, placenta separation, membrane rupture

# Fulminant hepatitis associated with hepatitis A virus super-infection in patients with chronic hepatitis C

- In a prospective study, 27/595 adults with chronic liver disease (HBV, n=163) and chronic HCV, n=432) developed acute hepatitis A
- **17/27** patients who developed acute HAV had chronic HCV infection
- **7/10** patients with chronic HCV developed fulminant hepatitis A Vs 0/10 HBV patients



## Increased incidence of fulminant hepatitis A in previously unrecognized HBsAg carriers with acute hepatitis\*

- Incidence of liver failure - 3.2% in patients hospitalized for acute hepatitis, irrespective of etiology (5/157)
- Incidence of liver failure in HBsAg+ subjects – 20.3% (36/177);  $P < 0.001$

**Conclusion**: HBsAg carriers were at 9 Fold increased risk of fulminant hepatitis A than non-carriers

## Search for host and viral factors associated with an increased risk for development of fulminant hepatitis A

- In spite of the unique single HAV serotype, some genetic diversity has been evident from the sequencing data obtained from a large number of HAV isolates
- Based on sequence variations at the VP1/2A junction, genotypes and subgenotypes have been defined
- So far - no confirmed correlation was found between defined HAV sequences and increased risk for developing fulminant hepatitis A. However the issue remains open.

# Viral Risk factors associated with fulminant HAV\*

- 19/76 subjects with acute ALF and encephalopathy were significantly older, had higher bilirubin levels, and were more likely to be females. (older age was not confirmed by multivariate analysis)
- 40/76 patients reported intake of medications of whom 19 took acetaminophen (<3.0gr/day) for less than 3 days
- 36/50 patients with available serum were HAV-RNA positive (>100 copies/ml)
- Phylogenetic analysis revealed 18 patients with genotype 1A, 12 patients 1B and 4 patients with genotype 3
- 9/19 patients with fulminant hepatitis A and encephalopathy had undetectable HAV-RNA (VP1/2A PCR), compared to 5/31 controls without ALF (P<.02)
- 8/19 patients recovered spontaneously and 10 were transplanted
- High bilirubin levels and low viremia were significantly related to risk of death or transplantation by multivariate analysis

## Selected day 1 clinical features of patients with FH - ALFSG\*

|                           | Spontaneous survival | Transplanted /Died | P     |
|---------------------------|----------------------|--------------------|-------|
| Age                       | 44                   | 54                 | NS    |
| Female (%)                | 69                   | 23                 | .008  |
| MELD score                | 29                   | 34                 | NS    |
| ALT (u) at admis..03      | 3362                 | 1675               | .03   |
| Alk. Phosphat.            | 179                  | 118                | .02   |
| Creatinine >2md/dl        | 13%                  | 54%                | NS    |
| Grade 3- 4 encephalopathy | 38%                  | 69%                | NS    |
| Pressors                  | 0%                   | 46%                | .0004 |
| Intubation                | 25%                  | 85%                | .01   |

\*Taylor RM et al. Hepatology 2006;44:1589

## Models to Predict Transplant/Death in 29 Patients With Hepatitis A Enrolled in the Acute Liver Failure Study Group

| <u>Model</u>               | <u>n</u>  | <u>Sensitivity</u> | <u>Specificity</u> | <u>PPV</u>  | <u>NPV</u>  | <u>AURO</u> |
|----------------------------|-----------|--------------------|--------------------|-------------|-------------|-------------|
| <b><u>ALFSG index*</u></b> |           |                    |                    |             |             |             |
| <b>≥1 Factor</b>           | <b>20</b> | <b>100%</b>        | <b>56%</b>         | <b>65%</b>  | <b>100%</b> | <b>.781</b> |
| <b>≥2 Factors</b>          | <b>14</b> | <b>92%</b>         | <b>88%</b>         | <b>86%</b>  | <b>93%</b>  | <b>.899</b> |
| <b>≥3 Factors</b>          | <b>9</b>  | <b>62%</b>         | <b>94%</b>         | <b>89%</b>  | <b>75%</b>  | <b>.766</b> |
| <b>4 Factors</b>           | <b>1</b>  | <b>8%</b>          | <b>100%</b>        | <b>100%</b> | <b>57%</b>  | <b>.538</b> |
| <b><u>Other models</u></b> |           |                    |                    |             |             |             |
| <b>MELD ≥35</b>            | <b>9</b>  | <b>54%</b>         | <b>88%</b>         | <b>78%</b>  | <b>70%</b>  | <b>.707</b> |
| <b>King's College</b>      | <b>5</b>  | <b>31%</b>         | <b>94%</b>         | <b>80%</b>  | <b>62%</b>  | <b>.623</b> |

\*Taylor RM et al. Hepatology 2006;44:1589

# Phylogenetic analysis of HAV in sera of Japanese patients with fulminant hepatitis

- Association between severity of hepatitis and genomic variations
- Mutations at the 5' NCR corresponding to the internal ribosome entry site may increase severity of liver disease in HAV (N=27 patients)
- Full length genome study in 3 patients suggests that these changes are not related to genotype
- Similar changes were also found in HAV adopted for growth in tissue culture

Investigators conclusion: Genetic organization of HAV may influence replication and virulence

---

*Fujiwara K. et al. Dig Dis Sci 2000;45:2422*

*Fujiwara K et al. J Hepatol 2001;35:112*

*Fujiwara K et al. Liver Int 2005;25:194*

*Fujiwara K et al. Liver Int 2008, Epub*

## Molecular characterization of HAV in children with fulminant hepatic failure in Argentina: 9/2003-1/2006\*

- N=41 children, age M 6.8y (1-15y), 22F/19M
- HAV-RNA analyzed through probes of the 5' non-coding and VP1/2A regions
- 18/41 HAV cases positive for the 5' NCR (39%) and 18/41 HAV cases for the VP1/2A region (39%)
- FHF variants had some minor differences in nucleotide or amino acid sequences as compared to self limited acute HAV cases with no common pattern of substitution, temporal and geographic parameters

# Putative Host Factors (Familial Clustering)\*

- 3 siblings developed fulminant hepatitis A in a family in Israel
- Cloning and sequencing of HAV in progress



# Conclusions

- The incidence of fulminant hepatitis A is low but there seems to be an increase in reports in children
- Improved intensive care and liver transplantation have markedly changed the fatality rates from fulminant hepatitis A
- Major risk factors include age, underlying liver disease and intake of paracetamol
- Conflicting and yet unconfirmed data have been reported on minor genetic substitutions of viral sequences with a putative impact on viral replication and cytopathic effect

Thank You



**The Hadassah-Hebrew University Campus – Jerusalem, Israel**